BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kirou KA, Dall`era M, Aranow C, Anders H. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol 2022;13:980079. [DOI: 10.3389/fimmu.2022.980079] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Dernoncourt A, Liabeuf S, Bennis Y, Masmoudi K, Bodeau S, Laville S, Hurtel-Lemaire AS, Gras-Champel V, Batteux B. Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase(®)). BioDrugs 2023;37:73-87. [PMID: 36401769 DOI: 10.1007/s40259-022-00564-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Raftopoulou S, Rapti A, Karathanasis D, Evangelopoulos ME, Mavragani CP. The role of type I IFN in autoimmune and autoinflammatory diseases with CNS involvement. Front Neurol 2022;13. [DOI: 10.3389/fneur.2022.1026449] [Reference Citation Analysis]